FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: Comparison with tissue plasminogen activator

Journal of Cerebral Blood Flow and Metabolism

Volumn 25, Issue 1, 2005, Pages 108-118

  Maeda, Masashi ^a   Moriguchi, Akira ^a   Mihara, Kayoko ^a   Aoki, Toshiaki ^a   Takamatsu, Hiroyuki ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

FK419; GPIIb IIIa; Monkey; Platelet; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FK 419; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; IN VITRO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PETECHIA; PRIORITY JOURNAL; SQUIRREL MONKEY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

ANIMALS; BLOOD PLATELETS; BRAIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICROCIRCULATION; MIDDLE CEREBRAL ARTERY; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPIONIC ACIDS; RECOVERY OF FUNCTION; REPERFUSION INJURY; SAIMIRI; TISSUE PLASMINOGEN ACTIVATOR;

EID: 11844291391     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600013     Document Type: Article

References (49)

1. AbESTT Investigators (2003) Effects of abciximab for acute ischemic stroke: Final results of Abciximab in Emergent Stroke Treatment Trial (AbESTT). Stroke 34:253
2. 3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 31:1402-10
3. Alexandrov AV, Grotta JC (2002) Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59:862-7
4. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-9
5. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R (2000) Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31:1240-9
6. Choudhri TF, Hoh BL, Zerwes H-G, Prestigiacomo CJ, Kim SC, Connolly Jr ES, Kottirsch G, Pinsky DJ (1998) Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 102:1301-10
7. Crowell RM, Olsson Y, Klatzo I, Ommaya A (1970) Temporary occlusion of the middle cerebral artery in the monkey: Clinical and pathological observations. Stroke 1:439-48
8. Dangas G, Marmur JD, King TE, Leon JD, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA (1999) Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 138:49-54
9. del Zoppo GJ, Copeland BR, Anderchek K, Hacke W, Koziol JA (1990) Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke 21:596-601
10. del Zoppo GJ, Mabuchi T (2003) Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 23:879-94
11. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee Jr R, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32:78-86
12. del Zoppo GJ, Schmid-Schönbein GW, Mori E, Copeland BR, Chang C-M (1991) Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22:1276-1283
13. Domanovits H, Nikfardjam M, Janata K, Hornykewycz S, Maurer G, Laggner AN, Huber K (1998) Restoration of coronary blood flow by single bolus injection of the GPIIb/IIIa receptor antagonist c7E3 Fab in a patient with acute myocardial infarction of recent onset. Clin Cardiol 21:525-8
14. Gillilan LA (1968) The arterial and venous blood supplies to the forebrain (including the internal capsule of primates. Neurology 18:653-70
15. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC (1997) Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 95:1755-9
16. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, Hacke W (1998) Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 80:298-301
17. Heo JH, Lee KY, Kim SH, Kim DI (2003) Immediate reocclusion following a successful thrombolysis in acute stroke: A pilot study. Neurology 60:1684-7
18. Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM (1998) Effect of SR121566A, a potent GPIIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 79:383-8
19. Herijgers P, Flameng W (1991) Coronary artery thrombosis and throbolysis in baboons: the effect of atenolol treatment on myocardial infarct size. Eur Heart J 12:1084-8
20. Hudgins WR, Garcia JH (1970) Transorbital approach to the middle cerebral artery of the squirrel monkey: A technique for experimental cerebral infarction applicable to ultrastructural studies. Stroke 1:107-11
21. International Stroke Trial Collaborative Group (1997) The international stroke trial (IST); A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-81
22. Ishikawa A, Ohata T, Imamura K, Iwasaki M, Sakai T, Matsuzawa T, Okazaki S (1997) Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys. J Toxicol Sci 22:117-33
23. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Mommel M (1999) Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 30:1326-32
24. Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, Nakashima M (1998) Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol 345:185-92
25. Kaku S, Umemura K, Yano S, Suzuki K, Kawasaki T, Nakashima M (1999) YM337, a platelet glycoprotein IIb/IIIa antagonist, lessens photochemically- induced ischemic brain damage in monkeys. Drug Dev Res 45:162-9
26. Kano T, Katayama Y, Tejima E, Lo EH (2000) Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 854:245-8
27. Kawano K, Fujishima K, Ikeda Y, Kondo K, Umemura K (2000) ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab 20:988-97
28. Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D (1993) A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 13:1837-42
29. Koudstaal PJ, Ciabattoni G, van Gijn J, Nieuwenhuis HK, de Groot PG, Sixma JJ, Patrono C (1993) Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 24:219-23
30. Lijnen HR, Marafino Jr BJ, Collen D (1984) In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species. Thromb Haemostas 52:308-10
31. Maeda M, Furuichi Y, Ueyama N, Moriguchi A, Satoh N, Matsuoka N, Goto T, Yanagihara T (2002) A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: Increased neuroprotective efficacy and extended therapeutic time window. J Cereb Blood Flow Metab 22:1205-11
32. Marciniak Jr SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL (2002) An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 87:1020-5
33. Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Asai Y, Muranaka Y, Nakashima M (1993) A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasminogen activator chimera in this model. J Pharmacol Toxicol Methods 29:165-73
34. Mihara K, Aoki T, Moriguchi A, Yamamoto H, Maeda M, Tojo N, Yamanaka T, Ohkubo M, Matsuoka N, Seki J, Mutoh S (2004) Characterization of the anti-platelet actions of FK419, a novel non-peptide antagonist of platelet GPIIb/IIIa. Drug Dev Res 61:233-41
35. Moriguchi A, Aoki T, Mihara K, Tojo N, Matsuoka N, Mutoh S (2004a) Antithrombotic effects of FK419, a novel non-peptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: Comparison with ozagrel and argatroban. J Pharmacol Exp Ther 308:1094-101
36. Moriguchi A, Maeda M, Mihara K, Aoki T, Matsuoka N, Mutoh S (2005) FK419, a novel neuropeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in guinea pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban. J Cereb Blood Flow Metab 25, 75-86
37. Moriguchi A, Mihara K, Aoki T, Maeda M, Tojo N, Matsuoka N, Mutoh S (2004b) Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig. Eur J Pharmacol 498:179-88
38. Mousa SA, Forsythe MS, Diemer M, Bozarth JM, Reilly TM (1994) Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728. Coron Artery Dis 5:919-27
39. Osborne KA, Shigeno T, Balarsky AM, Ford I, McCulloch J, Teasdale GM, Graham DI (1987) Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatry 50:402-10
40. Rosen GD, Harry JD (1990) Brain volume estimation from serial section measurements: a comparison of methodologies. J Neurosci Methods 35:115-24
41. STAIR (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-8
42. 2, and tissue plasminogen activator in focal ischemia: Evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab 22:215-22
43. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (NINDS) (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-7
44. 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 88:137-46
45. 2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24:1077-1082
46. van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, van Gijn J, Koudstaal PJ (1994) Evidence for episodic platelet activation in acute ischemic stroke. Stroke 25:278-81
47. 2 in a model of focal cerebral ischemia in rats. J Neurosurg 94:582-8
48. Zeller JA, Tschoepe D, Kessler C (1999) Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 81:373-377
49. Zhang ZG, Zhang L, Tsang W, Goussev A, Powers C, Ho K-L, Morris D, Smyth SS, Coller BS, Chopp M (2001) Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 912:181-94